COMMUNIQUÉS West-GlobeNewswire

Retrophin Announces U.S. FDA Acceptance of NDA Filing for the New Formulation of Thiola® (tiopronin) in the Treatment of Cystinuria
12/11/2018
PDUFA date set for June 30, 2019 SAN DIEGO, Nov. 12, 2018 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ: RTRX) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the New Drug [...]
Kamada Reports Financial Results for Third Quarter and First Nine Months of 2018
12/11/2018
Total Revenues for First Nine Months of 2018 were $66.3 Million, a 1% Decrease Year-Over-Year Gross Profit for First Nine Months of 2018 was $20.2 million, a 1% Decrease Year-Over-Year Adjusted EBITDA was $7.4 Million [...]
Amicus Therapeutics to Present at the Credit Suisse 27th Annual Healthcare Conference
12/11/2018
CRANBURY, N.J., Nov. 12, 2018 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that John F. Crowley, Chairman and Chief Executive Officer, will present a corporate overview at the Credit Suisse [...]
Matinas BioPharma Reports Third Quarter 2018 Financial Results and Provides Corporate Update
12/11/2018
– Key focus on advancing the development of MAT9001, a proprietary, potential best-in-class cardiovascular therapy in what is projected to be a new, multi-billion dollar prescription-only omega-3 drug class – – Company [...]
Mersana Scientists Present Updates on XMT-1522, XMT-1536 and the Dolaflexin Platform at World ADC 2018
12/11/2018
Mersana Chief Scientific Officer, Timothy B. Lowinger, Ph.D. to chair 2018 Conference CAMBRIDGE, Mass., Nov. 12, 2018 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical [...]
ContraFect Appoints Michael Messinger as Chief Financial Officer
12/11/2018
YONKERS, N.Y., Nov. 12, 2018 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq:CFRX) , a clinical-stage biotechnology company focused on the discovery and development of protein and antibody therapeutics for life- [...]
Oncolytics Biotech® Reports 2018 Third Quarter Financial Results and Provides Corporate Update
12/11/2018
- Checkpoint combination studies support progression into registration pathway for metastatic breast cancer and potential expansion of indications - - Management to host webcast and conference call today at 8:30 a.m. ET [...]
Ziopharm Oncology Announces $50 Million Private Placement
12/11/2018
BOSTON, Nov. 12, 2018 (GLOBE NEWSWIRE) -- Ziopharm Oncology, Inc. (Nasdaq: ZIOP), today announced that it has entered into definitive securities purchase agreements for the sale of its common stock and warrants to [...]
MatriSys Bioscience appoints Magda Marquet, PhD to the Board of Directors
12/11/2018
SAN DIEGO, Nov. 12, 2018 (GLOBE NEWSWIRE) -- MatriSys B ioscience, Inc ., a leader in the field of microbiome-based therapeutics for the treatment of skin conditions, is pleased to announce the appointment of Dr. Magda [...]
AC Immune to Present at the Jefferies 2018 London Healthcare Conference
12/11/2018
Lausanne, Switzerland, November 12, 2018 - AC Immune SA (NASDAQ: ACIU), a Swiss-based, clinical-stage biopharmaceutical company with a broad pipeline focused on neurodegenerative diseases, today announced that it will [...]
Rule 2.9 Announcement
12/11/2018
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION. 12 November 2018 [...]
Appointment of Joint Broker
12/11/2018
Summit Therapeutics plc (‘Summit’ or the ’Company’) Appointment of Joint Broker Oxford, UK, and Cambridge, MA, US, 12 November 2018 – Summit Therapeutics plc (NASDAQ: SMMT, AIM: SUMM), a leader in new mechanism [...]
Publication of Scheme Document
12/11/2018
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION FOR [...]
Innate Pharma presented translational data from the Phase II of monalizumab and cetuximab at SITC
12/11/2018
SITC 2018: FURTHER ANALYSES OF THE PHASE II STUDY OF THE COMBINATION OF MONALIZUMAB AND CETUXIMAB IN HEAD AND NECK PATIENTS SHOW ENCOURAGING SURVIVAL DATA IN BOTH SUBGROUPS OF IO-NAÏVE AND IO-PRETREATED SCCHN PATIENTS [...]
Innate Pharma a présenté des données translationnelles de la Phase II de monalizumab avec cetuximab au SITC
12/11/2018
SITC 2018 : DES ANALYSES COMPLEMENTAIRES DE LA PHASE II DE LA COMBINAISON DE MONALIZUMAB ET CETUXIMAB DANS LES CANCERS DE LA TÊTE ET DU COU MONTRENT DES DONNÉES DE SURVIE ENCOURAGEANTES DANS LES DEUX SOUS-GROUPES DE [...]
Addex to Present at the Biotech and Money Inv€$tival Showcase and Participate in the Jefferies London Healthcare Conference
12/11/2018
Geneva, Switzerland, 12 th November 2018 – Addex Therapeutics (SIX: ADXN), a leading company pioneering allosteric modulation-based drug discovery and development, announced today that CEO, Tim Dyer, will provide a [...]
Clinically Meaningful Outcome in NIH Trial of MPC-150-IM for Heart Failure LVAD Recipients Provides Pathway for Potential Regulatory Approval
12/11/2018
NEW YORK and MELBOURNE, Australia, Nov. 11, 2018 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB) today announced that results from a 159-patient randomized, sham-controlled Phase 2 trial in end-stage heart [...]
BioPorto A/S increases the share capital through a cash issue, private placement.
11/11/2018
November 11, 2018 Announcement no. 19 BioPorto A/S increases the share capital through a cash issue, private placement. NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES [...]
New Novartis study supports Entresto as foundational HFrEF therapy and in-hospital initiation in appropriate stabilized heart failure patients
11/11/2018
Entresto ® (sacubitril/valsartan) outperformed commonly used heart failure medicine enalapril in landmark study; delivered significantly greater and more rapid reductions in an established biomarker for heart failure [...]

Pages